Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

This "Liquid Biopsy" Biotech Popped 20% on Friday – With More to Come

Shares of TrovaGene Inc. (Nasdaq: TROV), the San Diego-based biotech we recommended to you back on March 11, soared more than 20% on Friday after the company said clinical research showed that its "liquid biopsy" test did a better job detecting metastatic lung cancer than its tissue-biopsy counterpart.

In fact, with Friday's close at $8.53 a share, TrovaGene's stock price has now climbed more than 36% from our recommendation price of $6.23 a share.

Full Story

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK